Cargando…

Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2

BACKGROUND: Given that only 25% of pregnant women elect to receive a COVID-19 vaccine, maternal SARS-CoV-2 infection remains an important route of conferring protective passive immunity to breastfed infants of mothers who are not vaccinated. METHODS: We enrolled 30 lactating participants between Dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayanaswamy, Vignesh, Pentecost, Brian T., Telfer, Janice C., Burnside, Amy S., Schneider, Sallie S., Alfandari, Dominique, Baker, Ryan L., Saiju, Aman, Nodiff, Sam, Arcaro, Kathleen F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512087/
https://www.ncbi.nlm.nih.gov/pubmed/36172379
http://dx.doi.org/10.3389/fimmu.2022.985226
_version_ 1784797779983335424
author Narayanaswamy, Vignesh
Pentecost, Brian T.
Telfer, Janice C.
Burnside, Amy S.
Schneider, Sallie S.
Alfandari, Dominique
Baker, Ryan L.
Saiju, Aman
Nodiff, Sam
Arcaro, Kathleen F.
author_facet Narayanaswamy, Vignesh
Pentecost, Brian T.
Telfer, Janice C.
Burnside, Amy S.
Schneider, Sallie S.
Alfandari, Dominique
Baker, Ryan L.
Saiju, Aman
Nodiff, Sam
Arcaro, Kathleen F.
author_sort Narayanaswamy, Vignesh
collection PubMed
description BACKGROUND: Given that only 25% of pregnant women elect to receive a COVID-19 vaccine, maternal SARS-CoV-2 infection remains an important route of conferring protective passive immunity to breastfed infants of mothers who are not vaccinated. METHODS: We enrolled 30 lactating participants between December 2020 and March 2021 who had a positive PCR-test and their first COVID-19 symptoms within the previous 21 days. Participants were asked to provide serial bilateral milk samples at 12 timepoints (~ every 3 days) over a period of 35 days. A second set of samples was collected at least four months after the beginning of the first set. Participants also were asked to provide their dried blood spots and infant stool samples. All samples were tested for receptor-binding domain (RBD)-specific immunoglobulin (Ig)A, IgG, and IgM. Milk samples were assessed for neutralizing ability against the spike protein and four SARS-CoV-2 variants: D614G, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1). Permeability of the breast epithelium was assessed by measuring the sodium to potassium ions (Na:K) in milk. Using flow cytometry, memory CD4 and CD8 T cells (CD45RO(+) and CCR7(+/-)) and mucosal-homing CD4 and CD8 T cells (CD103(+)) were determined in cells from milk expressed at 35 days and at least 4 months after their first milk donation. RESULTS: Milk antibodies from SARS-CoV-2 positive participants neutralized the spike complex. Milk from 73, 90, and 53% of participants had binding reactivities to RBD-specific IgA, IgG, and IgM, respectively. In contrast to blood spots, which showed increased levels of IgG, but not IgA or IgM, the COVID-19 response in milk was associated with a robust IgA response. Twenty-seven percent of participants had increased breast-epithelium permeability, as indicated by Na:K ≥ 0.6. The percentage of CD45RO(+)CCR7(-) effector-memory T cells in the day ≥120 milk samples was significantly higher than day 35 samples (P< 0.05). CONCLUSIONS: Antibodies in milk from participants with recent SARS-CoV-2 infection and those who recovered can neutralize the spike complex. For the first time we show that breastmilk T cells are enriched for mucosal memory T cells, further emphasizing the passive protection against SARS-CoV-2 conferred to infants via breastmilk.
format Online
Article
Text
id pubmed-9512087
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95120872022-09-27 Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2 Narayanaswamy, Vignesh Pentecost, Brian T. Telfer, Janice C. Burnside, Amy S. Schneider, Sallie S. Alfandari, Dominique Baker, Ryan L. Saiju, Aman Nodiff, Sam Arcaro, Kathleen F. Front Immunol Immunology BACKGROUND: Given that only 25% of pregnant women elect to receive a COVID-19 vaccine, maternal SARS-CoV-2 infection remains an important route of conferring protective passive immunity to breastfed infants of mothers who are not vaccinated. METHODS: We enrolled 30 lactating participants between December 2020 and March 2021 who had a positive PCR-test and their first COVID-19 symptoms within the previous 21 days. Participants were asked to provide serial bilateral milk samples at 12 timepoints (~ every 3 days) over a period of 35 days. A second set of samples was collected at least four months after the beginning of the first set. Participants also were asked to provide their dried blood spots and infant stool samples. All samples were tested for receptor-binding domain (RBD)-specific immunoglobulin (Ig)A, IgG, and IgM. Milk samples were assessed for neutralizing ability against the spike protein and four SARS-CoV-2 variants: D614G, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1). Permeability of the breast epithelium was assessed by measuring the sodium to potassium ions (Na:K) in milk. Using flow cytometry, memory CD4 and CD8 T cells (CD45RO(+) and CCR7(+/-)) and mucosal-homing CD4 and CD8 T cells (CD103(+)) were determined in cells from milk expressed at 35 days and at least 4 months after their first milk donation. RESULTS: Milk antibodies from SARS-CoV-2 positive participants neutralized the spike complex. Milk from 73, 90, and 53% of participants had binding reactivities to RBD-specific IgA, IgG, and IgM, respectively. In contrast to blood spots, which showed increased levels of IgG, but not IgA or IgM, the COVID-19 response in milk was associated with a robust IgA response. Twenty-seven percent of participants had increased breast-epithelium permeability, as indicated by Na:K ≥ 0.6. The percentage of CD45RO(+)CCR7(-) effector-memory T cells in the day ≥120 milk samples was significantly higher than day 35 samples (P< 0.05). CONCLUSIONS: Antibodies in milk from participants with recent SARS-CoV-2 infection and those who recovered can neutralize the spike complex. For the first time we show that breastmilk T cells are enriched for mucosal memory T cells, further emphasizing the passive protection against SARS-CoV-2 conferred to infants via breastmilk. Frontiers Media S.A. 2022-09-12 /pmc/articles/PMC9512087/ /pubmed/36172379 http://dx.doi.org/10.3389/fimmu.2022.985226 Text en Copyright © 2022 Narayanaswamy, Pentecost, Telfer, Burnside, Schneider, Alfandari, Baker, Saiju, Nodiff and Arcaro https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Narayanaswamy, Vignesh
Pentecost, Brian T.
Telfer, Janice C.
Burnside, Amy S.
Schneider, Sallie S.
Alfandari, Dominique
Baker, Ryan L.
Saiju, Aman
Nodiff, Sam
Arcaro, Kathleen F.
Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2
title Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2
title_full Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2
title_fullStr Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2
title_full_unstemmed Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2
title_short Durable antibody and effector memory T cell responses in breastmilk from women with SARS-CoV-2
title_sort durable antibody and effector memory t cell responses in breastmilk from women with sars-cov-2
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512087/
https://www.ncbi.nlm.nih.gov/pubmed/36172379
http://dx.doi.org/10.3389/fimmu.2022.985226
work_keys_str_mv AT narayanaswamyvignesh durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT pentecostbriant durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT telferjanicec durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT burnsideamys durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT schneidersallies durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT alfandaridominique durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT bakerryanl durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT saijuaman durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT nodiffsam durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2
AT arcarokathleenf durableantibodyandeffectormemorytcellresponsesinbreastmilkfromwomenwithsarscov2